Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 5/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.48 |
| ▸ | PTGIR | P43119 | 3/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.48 |
| ▸ | PTGFR | P43088 | 2/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 14/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5420470 | 1.00 | PTGDR (0.48) | PTGDRTBXA2RPTGER3PTGER2PTGIR | |
| SCHEMBL1255235 | 0.93 | PDE2A (0.50) | PTGDRTBXA2RPTGER3PTGER2PTGIR | |
| SCHEMBL14562372 | 0.82 | HTR2A (0.36) | PTGDRTBXA2RPTGER3PTGER2PTGIR | |
| SCHEMBL13407089 | 0.82 | HTR2A (0.36) | PTGDRTBXA2RPTGER3PTGER2PTGIR | |
| SCHEMBL5424892 | 0.81 | PTGDR (0.52) | PTGDRTBXA2RPTGER3PTGER2PTGIR | |
| SCHEMBL6820539 | 0.81 | TBXA2R (0.53) | PTGDRTBXA2RPTGER2S1PR1 | |
| SCHEMBL9518113 | 0.81 | TBXA2R (0.48) | PTGDRTBXA2RS1PR1PDE2A | |
| SCHEMBL5526809 | 0.79 | S1PR1 (0.40) | S1PR1S1PR4ADORA3S1PR5 | |
| SCHEMBL4101457 | 0.78 | CYP11B1 (0.41) | PTGDRTBXA2RS1PR1PDE2A | |
| SCHEMBL5421567 | 0.78 | S1PR1 (0.59) | S1PR1S1PR4ADORA3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116244-B1 | Method of treating atherosclerosis, dyslipidemias and related conditions | SCHERING CORP (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120115921-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115921-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110118292-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | CHENG KANG | 2011-05-19 | — | — | US | disclosed |
| US-20110118292-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | CHENG KANG | 2011-05-19 | — | — | US | disclosed |
| EP-2286816-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100081696-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | BERTHELETTE CARL | 2010-04-01 | — | — | US | disclosed |
| US-20100081696-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | BERTHELETTE CARL | 2010-04-01 | — | — | US | disclosed |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | CHENG KANG | 2010-03-25 | — | — | US | disclosed |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | CHENG KANG | 2010-03-25 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | MERCK & CO., INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070054951-A1 | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists | MERCK FROSST CANADA & CO. (CA) | 2007-03-08 | — | — | US | disclosed |
| WO-2006089309-A2 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060069148-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | BERTHELETTE CARL | 2006-03-30 | — | — | US | disclosed |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | CHENG KANG (US) | 2004-11-18 | — | — | US | disclosed |
| US-20030158246-A1 | For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. | MERCK FROSST CANADA & CO. (CA) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069148-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | PTGER1, PTGER3, PTGER2 | PTGDR 7/4885TBXA2R 17/4885PTGER3 2/4885 |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | PTGDR 518/4885TBXA2R 53/4885PTGER3 713/4885 |
| US-20120115921-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | PTGER1, PTGER3, PTGER2 | PTGDR 7/4885TBXA2R 17/4885PTGER3 2/4885 |
| US-20030158246-A1 | For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. | PTGES, PTGIR, PTGER1 | PTGDR 14/4885TBXA2R 25/4885PTGER3 7/4885 |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | LDLR, LPAR5, FFAR1 | PTGDR 164/4885TBXA2R 44/4885PTGER3 250/4885 |
| US-20070054951-A1 | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists | PTGDR2, PTGER2, PTGDR | PTGDR 3/4885TBXA2R 18/4885PTGER3 7/4885 |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | PTGDR 591/4885TBXA2R 44/4885PTGER3 574/4885 |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | LDLR, LIPA, APOB | PTGDR 97/4885TBXA2R 68/4885PTGER3 139/4885 |
| US-20100081696-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | PTGER1, PTGER3, PTGER2 | PTGDR 7/4885TBXA2R 17/4885PTGER3 2/4885 |
| US-20110118292-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | LDLR, HCAR1, FFAR1 | PTGDR 201/4885TBXA2R 37/4885PTGER3 497/4885 |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | LDLR, HCAR1, FFAR1 | PTGDR 201/4885TBXA2R 37/4885PTGER3 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.